189 related articles for article (PubMed ID: 30235730)
1. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Huang G; Zhai J; Huang X; Zheng D
Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.
Upshaw JN; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Arndt L; Domchek S; DeMichele A; Fox K; Shah P; Clark A; Bradbury A; Matro J; Adusumalli S; Carver JR; Ky B
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 2):198-210. PubMed ID: 31542526
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
4. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
7. Association between clinical risk factors and left ventricular function in patients with breast cancer following chemotherapy.
Yamashita K; Tanaka H; Hatazawa K; Tanaka Y; Sumimoto K; Shono A; Suzuki M; Yokota S; Suto M; Mukai J; Takada H; Matsumoto K; Minami H; Hirata KI
Int J Cardiovasc Imaging; 2021 Jan; 37(1):197-205. PubMed ID: 32860123
[TBL] [Abstract][Full Text] [Related]
8. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
11. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
12. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
13. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.
Barron CC; Alhussein MM; Kaur U; Cosman TL; Tyagi NK; Brown M; Mukherjee SD; Ellis PM; Dhesy-Thind S; Leong DP
Curr Oncol; 2019 Aug; 26(4):240-246. PubMed ID: 31548803
[TBL] [Abstract][Full Text] [Related]
17. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
Barthur A; Brezden-Masley C; Connelly KA; Dhir V; Chan KK; Haq R; Kirpalani A; Barfett JJ; Jimenez-Juan L; Karur GR; Deva DP; Yan AT
J Cardiovasc Magn Reson; 2017 Apr; 19(1):44. PubMed ID: 28395671
[TBL] [Abstract][Full Text] [Related]
19. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
El-Sherbeny WS; Sabry NM; Sharbay RM
J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
[TBL] [Abstract][Full Text] [Related]
20. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
